Dexcom G6 Continuous Glucose Monitoring in Hemodialysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-01

Study Completion Date

2023-12-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot study enrolling adult hemodialysis patients with diabetes recruited from the University of California Irvine Medical Center (UCIMC) who will undergo simultaneous measurement of glucose levels using 1) continuous glucose monitor (CGM) measured by a Dexcom G6 device vs. 2) "gold-standard" blood glucose levels using capillary fingerstick or venous blood glucose measurements obtained on a point of care (POC) blood glucose meter. The study will assess Dexcom G6 accuracy by comparing glucose levels on the CGM device vs. blood glucose measurements in the study population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improved Glycemic Control in Diabetic Patients in Hemodialysis Using Continuous Glucose Monitoring (CGM)

NCT05678712

Hemodialysis Type1diabetes Type2Diabetes

COMPLETED NA

Use of CGM in Kidney Transplant Recipients

NCT04783441

Kidney Transplant; Complications Diabetes Mellitus, Type 2 Insulin Dependent Diabetes

RECRUITING NA

Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial

NCT05509881

Hemodialysis Diabete Mellitus Continuous Glucose Monitoring

RECRUITING NA

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430

End-Stage Renal Disease Type 2 Diabetes

COMPLETED NA

Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).

NCT04094064

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Hemodialysis Glucose Measurement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexcom G6 Continuous Glucose Monitor

Group Type EXPERIMENTAL

Dexcom G6 Continuous Glucose Monitor

Intervention Type DEVICE

Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexcom G6 Continuous Glucose Monitor

Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult hemodialysis patients age 18 years or older
* Have a comorbidity of diabetes
* Receipt of care from the inpatient University of California Irvine Medical Center nephrology consult service
* Expected hospital stay ≥48 hours
* Have the ability to directly provide informed consent for participation in the study

Exclusion Criteria

* Critically-ill patients receiving care in the intensive care unit (ICU) or cardiac care unit (CCU)
* Moribund patients expected to die within 48 hours
* Presence of any condition deemed by PI's judgment that would seriously limit life expectancy (i.e., poor survival)
* Pregnant
* Unwilling or unable to provide informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No